Abstract:Glioblastoma (GBM) is the most frequent and malignant brain tumor with a high mortality rate. The presence of a large population of macrophages (Mφ) in the tumor microenvironment is a prominent feature of GBM and these so-called tumor-associated Mφ (TAM) closely interact with the GBM cells to promote the survival, progression and therapy resistance of the GBM. Various therapeutic strategies have been devised either targeting the GBM cells or the TAM but few have addressed the cross-talks between the two cell populations. The present study was carried out to explore the possibility of exploiting the cross-talks between the GBM cells (GC) and TAM for modulation of the GBM microenvironment through using Nano-DOX, a drug composite based on nanodiamonds bearing doxorubicin. In the in vitro work on human cell models, Nano-DOX-loaded TAM were first shown to be viable and able to infiltrate three-dimensional GC spheroids and release cargo drug therein. GC were then demonstrated to encourage Nano-DOX-loaded TAM to unload Nano-DOX back into GC which consequently emitted damage-associated molecular patterns (DAMPs) that are powerful immunostimulatory agents as well as indicators of cell damage. Nano-DOX was next proven to be a more potent inducer of GC DAMPs emission than doxorubicin. As a result, Nano-DOX-damaged GC exhibited an enhanced ability to attract both TAM and Nano-DOX-loaded TAM. Most remarkably, Nano-DOX-damaged GC reprogrammed the TAM from a pro-GBM phenotype to an anti-GBM phenotype that suppressed GC growth. Finally, the in vivo relevance of the in vitro findings was tested in animal study. Mice bearing orthotopic human GBM xenografts were intravenously injected with Nano-DOX-loaded mouse TAM which were found releasing drug in the GBM xenografts 24h after injection. GC damage was evidenced by the induction of DAMPs emission within the xenografts and a shift of TAM phenotype was detected as well. Taken together, our results demonstrate a novel way with therapeutic potential to harness the cross-talk between GBM cells and TAM for modulation of the tumor immune microenvironment.

Targeting Tumor Hypoxia Using Nanoparticle-engineered CXCR4-overexpressing Adipose-derived Stem Cells

Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation

Tumortropic Adipose-Derived Stem Cells Carrying Smart Nanotherapeutics for Targeted Delivery and Dual-Modality Therapy of Orthotopic Glioblastoma

Nanoparticle Engineered TRAIL-overexpressing Adipose-Derived Stem Cells Target and Eradicate Glioblastoma Via Intracranial Delivery

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy

Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature.

Potentiating dendritic cells to target hypoxic environment of brain tumor (TUM4P.911)

Targeted intracellular delivery of molecular cargo to hypoxic human breast cancer stem cells

Tumor Hypoxia-Activated Combinatorial Nanomedicine Triggers Systemic Antitumor Immunity to Effectively Eradicate Advanced Breast Cancer.

Nanocarriers Responsive To A Hypoxia Gradient Facilitate Enhanced Tumor Penetration And Improved Anti-Tumor Efficacy

Hypoxia-Targeting, Tumor Microenvironment Responsive Nanocluster Bomb for Radical-Enhanced Radiotherapy.

Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy

Harnessing the Cross-Talk Between Tumor Cells and Tumor-Associated Macrophages with a Nano-Drug for Modulation of Glioblastoma Immune Microenvironment.

Hypoxia-activated nanomedicines for effective cancer therapy

Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs

Human Adipose-Derived Mesenchymal Stem Cell-Secreted CXCL1 and CXCL8 Facilitate Breast Tumor Growth By Promoting Angiogenesis.

Reprogramming Hypoxic Tumor‐associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy

Targeted Nanodrugs to Destroy the Tumor Extracellular Matrix Barrier for Improving Drug Delivery and Cancer Therapeutic Efficacy

Hypoxia-Activated Prodrug Enabling Synchronous Chemotherapy and HIF-1α Downregulation for Tumor Treatment.

Active Targeting Co-Delivery of Therapeutic Sur Sirna and Antineoplastic Drug Via Epidermal Growth Factor Receptor Mediated Magnetic Nanoparticles for Synergistic Programmed Cell Death in Glioblastoma Stem Cells